BIOMARIN PHARMACEUTICAL INC Quarterly Cost of Revenue in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Biomarin Pharmaceutical Inc quarterly/annual Cost of Revenue history and growth rate from Q1 2010 to Q3 2024.
  • Biomarin Pharmaceutical Inc Cost of Revenue for the quarter ending September 30, 2024 was $188M, a 47.2% increase year-over-year.
  • Biomarin Pharmaceutical Inc Cost of Revenue for the twelve months ending September 30, 2024 was $565M, a 8.32% increase year-over-year.
  • Biomarin Pharmaceutical Inc annual Cost of Revenue for 2023 was $515M, a 6.45% increase from 2022.
  • Biomarin Pharmaceutical Inc annual Cost of Revenue for 2022 was $484M, a 2.8% increase from 2021.
  • Biomarin Pharmaceutical Inc annual Cost of Revenue for 2021 was $471M, a 10.3% decline from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $565M $188M +$60.4M +47.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $504M $130M -$160K -0.12% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $505M $125M -$10.3M -7.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-26
Q4 2023 $515M $121M -$6.57M -5.16% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 $521M $128M +$11.8M +10.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $510M $131M +$7.49M +6.09% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $502M $135M +$18.5M +15.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-26
Q4 2022 $484M $127M +$7.54M +6.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 $476M $116M +$12.8M +12.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $463M $123M -$3.94M -3.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $467M $117M -$3.2M -2.66% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q4 2021 $471M $120M -$6.39M -5.06% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 $477M $104M -$85.3M -45.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $562M $127M +$29.1M +29.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $533M $120M +$8.79M +7.89% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q4 2020 $524M $126M +$30.2M +31.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 $494M $189M +$91.8M +94.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $402M $98M +$20.5M +26.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $382M $111M +$22.2M +24.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $359M $95.9M +$20.9M +27.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 $339M $96.9M +$18.1M +22.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 $321M $77.4M -$1.58M -2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $322M $89.2M +$6.85M +8.32% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q4 2018 $315M $75M -$976K -1.28% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-26
Q3 2018 $316M $78.9M +$19.4M +32.6% Jul 1, 2018 Sep 30, 2018 10-Q/A 2019-11-04
Q2 2018 $297M $79M +$22.7M +40.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-02
Q1 2018 $274M $82.3M +$32.3M +64.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $242M $76M +$11.8M +18.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $230M $59.5M +$8.74M +17.2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-26
Q2 2017 $221M $56.3M +$4.69M +9.08% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 $217M $50M +$6.89M +16% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q4 2016 $210M $64.1M +$16.1M +33.5% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $194M $50.7M +$15.8M +45.4% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-31
Q2 2016 $178M $51.6M +$13.6M +35.6% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-02
Q1 2016 $164M $43.1M +$12.1M +39.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q4 2015 $152M $48M +$9.72M +25.4% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-26
Q3 2015 $142M $34.9M +$4.98M +16.7% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-03
Q2 2015 $137M $38.1M +$6.85M +22% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $130M $31M +$8.18M +35.9% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q4 2014 $122M $38.3M +$21.1M +122% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-27
Q3 2014 $101M $29.9M +$1.87M +6.65% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-02
Q2 2014 $99.4M $31.2M +$8.64M +38.3% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-05
Q1 2014 $90.7M $22.8M +$2.32M +11.3% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q4 2013 $88.4M $17.3M -$9.26M -34.9% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-29
Q3 2013 $97.7M $28.1M +$3.44M +14% Jul 1, 2013 Sep 30, 2013 10-Q 2014-10-28
Q2 2013 $94.2M $22.6M -$1.01M -4.27% Apr 1, 2013 Jun 30, 2013 10-Q 2014-07-31
Q1 2013 $95.2M $20.5M +$3.4M +19.8% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-02
Q4 2012 $91.8M $26.5M +$5.01M +23.3% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 $86.8M $24.6M +$2.17M +9.69% Jul 1, 2012 Sep 30, 2012 10-Q 2013-10-28
Q2 2012 $84.6M $23.6M +$4.31M +22.4% Apr 1, 2012 Jun 30, 2012 10-Q 2013-07-29
Q1 2012 $80.3M $17.1M -$3.69M -17.7% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-29
Q4 2011 $84M $21.5M +$1.05M +5.13% Oct 1, 2011 Dec 31, 2011 10-K 2014-02-26
Q3 2011 $83M $22.4M +$4.44M +24.7% Jul 1, 2011 Sep 30, 2011 10-Q 2012-10-29
Q2 2011 $78.5M $19.3M +$4.86M +33.8% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-02
Q1 2011 $73.7M $20.8M +$3.38M +19.4% Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-30
Q4 2010 $70.3M $20.5M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $18M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-31
Q2 2010 $14.4M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-01
Q1 2010 $17.4M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.